Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer

RAS (rat sarcoma virus) mutant cancers remain difficult to treat despite the advances in targeted therapy and immunotherapy. Targeted therapies against the components of mitogen-activated protein kinase (MAPK) pathways, including RAS, RAF, MEK, and ERK, have demonstrated activity in BRAF mutant and,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jennifer J., Jain, Vaibhav, Amaravadi, Ravi K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623813/
https://www.ncbi.nlm.nih.gov/pubmed/34830283
http://dx.doi.org/10.3390/ijms222212402

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623813/
https://www.ncbi.nlm.nih.gov/pubmed/34830283
http://dx.doi.org/10.3390/ijms222212402

Ejemplares similares